Wellington Management Group LLP Has $2.06 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Wellington Management Group LLP boosted its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 137.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,690 shares of the company's stock after buying an additional 81,354 shares during the quarter. Wellington Management Group LLP owned approximately 0.23% of Immunome worth $2,057,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC bought a new position in Immunome during the second quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Immunome in the 2nd quarter valued at approximately $97,000. Arizona State Retirement System lifted its holdings in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after purchasing an additional 918 shares during the last quarter. Intech Investment Management LLC acquired a new position in Immunome during the third quarter valued at approximately $219,000. Finally, AQR Capital Management LLC increased its stake in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after purchasing an additional 4,129 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IMNM shares. Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Stephens began coverage on Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price target for the company. Finally, Wedbush reissued an "outperform" rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $28.83.

Insider Activity

In other Immunome news, insider Robert Lechleider acquired 15,805 shares of Immunome stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares in the company, valued at $149,831.40. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall bought 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The shares were bought at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 102,862 shares of company stock valued at $978,045 over the last three months. 8.60% of the stock is owned by insiders.

Immunome Stock Down 0.3 %

IMNM stock traded down $0.03 during midday trading on Thursday, reaching $11.08. 1,029,238 shares of the company's stock traded hands, compared to its average volume of 780,202. The company has a market cap of $691.58 million, a price-to-earnings ratio of -1.37 and a beta of 1.83. Immunome, Inc. has a 1-year low of $8.05 and a 1-year high of $30.96. The company has a 50-day simple moving average of $12.17 and a two-hundred day simple moving average of $13.37.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.